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Abstract
Background: Retroviruses selectively encapsidate two copies of their genomic RNA, the Gag
protein binding a specific RNA motif in the 5' UTR of the genome. In human immunodeficiency virus
type 2 (HIV-2), the principal packaging signal (Psi) is upstream of the major splice donor and hence
is present on all the viral RNA species. Cotranslational capture of the full length genome ensures
specificity. HIV-2 RNA dimerisation is thought to occur at the dimer initiation site (DIS) located in
stem-loop 1 (SL-1), downstream of the main packaging determinant. However, the HIV-2 packaging
signal also contains a palindromic sequence (pal) involved in dimerisation. In this study, we analysed
the role of the HIV-2 packaging signal in genomic RNA dimerisation in vivo and its implication in
viral replication.
Results: Using a series of deletion and substitution mutants in SL-1 and the Psi region, we show
that in fully infectious HIV-2, genomic RNA dimerisation is mediated by the palindrome pal.
Mutation of the DIS had no effect on dimerisation or viral infectivity, while mutations in the
packaging signal severely reduce both processes as well as RNA encapsidation. Electron
micrographs of the Psi-deleted virions revealed a significant reduction in the proportion of mature
particles and an increase in that of particles containing multiple cores.
Conclusion: In addition to its role in RNA encapsidation, the HIV-2 packaging signal contains a
palindromic sequence that is critical for genomic RNA dimerisation. Encapsidation of a dimeric
genome seems required for the production of infectious mature particles, and provides a promising
therapeutic target.
Background
Retroviruses encapsidate two copies of the positive sense
single-stranded genomic RNA. Encapsidation is very spe-
cific, as the virus has to select and package the full length
genomic RNA over the vast excess of cellular and subge-
nomic RNA species. In human immunodeficiency virus
type 1 (HIV-1), this mechanism is well understood. An
RNA motif, downstream of the viral splice donor and
upstream of the Gag start codon, interacts with the Gag
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structural protein and ensures specificity of encapsidation
for full length rather than spliced RNAs [1-6].
In the case of HIV-2, the process is less well understood as
the main packaging determinant (Psi or Ψ) appears to be
located upstream of the major splice donor [7]. In a study
to further map the HIV-2 encapsidation signal, a 28 nucle-
otides (nt) sequence upstream of the splice donor was
identified as being required for HIV-2 RNA packaging [8].
To specifically encapsidate the unspliced genomic RNA,
HIV-2 has been demonstrated to package its genome in a
cis rather than a trans manner [9]. The structural Gag pro-
tein is translated from the full length RNA and encapsi-
dates the RNA from the same pool from which it was
translated [8,9].
The cis mechanism ensures that only the full length RNA
is packaged and provides the specificity. Nonetheless, the
requirement for specific sequences implies that an RNA
structure is involved in the process. For example, several in
vitro studies have shown that long-range interactions can
regulate RNA encapsidation and dimerisation, both in
HIV-1 and HIV-2 [10-13]. Furthermore, a recent study of
the HIV-2 5' leader region revealed that an extended stem-
loop 1 (SL-1) structure was required for efficient genome
encapsidation and viral replication [14].
Dimerisation of retroviral genomes is thought to be
linked to the encapsidation process, with elements for
both often overlapping [11,15-19]. The HIV-2 leader has
been extensively studied and a palindromic sequence
within the encapsidation signal has been identified and
shown to be important for the regulation of the dimerisa-
tion process in vitro [11,20]. In addition, several in vitro
studies proposed that a palindrome located in the loop of
SL-1 could act as the dimer initiation site (DIS) [21,22],
similarly to what has been shown in HIV-1 [23,24]. To
date, the dimeric nature of wild type HIV-2 RNA in cells
has yet not been confirmed.
In this study, we analysed a series of SL-1 and Psi mutant
viruses, including the 28 nt deletion containing virus
mentioned above. Interestingly, viruses deficient for dim-
erisation in vivo were also defective for encapsidation, rep-
lication and infectivity. The latter suggests a potential
maturation defect and electron microscopy (EM) was per-
formed on virions to determine whether or not this proc-
ess was affected.
We present here the results of these in vivo studies and pro-
pose that a previously identified motif, the DIS palin-
drome, is not required for efficient dimerisation of the
HIV-2 RNA in the virus. Our data suggest that genomic
RNA dimerisation is mediated by a sequence located
within the Psi region and that dimerisation may indeed be
closely linked to viral packaging. Importantly, dimerisa-
tion defective viruses are deficient in virion maturation
and infectivity, potentially offering new targets for inhib-
iting replication of HIV-2.
Results
Mutation of the HIV-2 packaging signal and DIS
We previously described the DM deletion mutant (Fig.
1A) of HIV-2 which shows a major packaging defect [8].
Recently, the formation of a stem, named stem B and
located at the base of SL-1 (Fig. 1B), was shown to be
required for efficient genome encapsidation and viral rep-
lication [14]. The sequence involved in the formation of
stem B is part of a 10 nt palindrome (pal), located within
the packaging signal Psi (Ψ), and which has been sug-
gested to play a role in RNA dimerisation in vitro [21]. To
investigate the requirement for this palindromic sequence
in HIV-2 dimerisation in vivo, we mutated the first four
bases of pal but maintained the bases involved in stem B
formation (Fig. 1A, SM2). In HIV-2, initiation of dimeri-
sation has been postulated to occur at the DIS, a palin-
drome located at the top of SL-1 (Fig. 1B) [21,22].
Interestingly, mutations of the HIV-1 DIS revealed that the
sequence was not required for genomic RNA dimerisation
in vivo or for viral replication in primary cells but was
important for replication in T cells [25,26]. Hence, we
decided to examine whether the HIV-2 DIS was required
for genomic RNA dimerisation and viral replication by
mutating the first three bases of the palindrome (Fig. 1A,
SM1).
None of the above described mutations had a significant
effect on protein production by the virus as judged by
western blot analysis (data not shown, [8]), even though
the reverse transcriptase (RT) activities of the DM and SM2
mutants were slightly reduced compared to that of the
wild type and SM1 mutant (data not shown), suggesting
that the virus production is slightly lower for the two Psi
mutants.
Mutations of the HIV-2 packaging signal, but not the DIS, 
reduce genomic dimerisation in vivo
We analysed the effect of the mutations in the packaging
signal (DM and SM2) and the DIS (SM1) on genomic
RNA dimerisation. Virion RNA extracted from wild type
and mutant HIV-2 was analysed by non-denaturing north-
ern blot (Fig. 2A) and the percentage of dimer present in
each sample was quantified by densitometry (Fig. 2B). RT
activity was measured to load RNA from an equivalent
amount of virus particles in each lane. Wild type HIV-2
RNA appeared mostly dimeric within the virion (80%,
Fig. 2B), whereas viruses bearing mutations in the Psi
region (DM and SM2) showed a significant defect in dim-
erisation, with around 30 to 35% dimer (Fig. 2B), in addi-
tion to a reduction in the apparent amount of RNARetrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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Genomic and structural context of the mutations introduced in the HIV-2 leader Figure 1
Genomic and structural context of the mutations introduced in the HIV-2 leader. (A) Genomic organisation of 
HIV-2 and location of the mutations introduced. The DM deletion mutant has been described previously [8]. In SM1 the first 
three bases in the DIS palindrome at position 420 of the HIV-2 RNA genome are substituted. In SM2 the first four bases of the 
Psi palindrome at position 392 of the HIV-2 RNA genome are substituted. (B) Structure of the SL-1 region predicted by previ-
ously published biochemical analyses [20, 22, 55, 56] and mfold computer modelling [57, 58. The position of the stem proposed 
to extend SL-1 is indicated (stem B) [14].Retrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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encapsidated (Fig. 2A). These results demonstrate that the
Psi region contains a signal essential for efficient dimeri-
sation in vivo and that at least part of it is mapped to the
palindrome pal. Surprisingly, mutation of the DIS palin-
drome does not have an effect on dimerisation in vivo and
80% of the genomic RNA packaged appears dimeric (Fig.
2A and 2B). This result contradicts data obtained in an in
vitro dimerisation assay, where short RNA transcripts har-
bouring the SM1 mutation did not dimerise efficiently
(data not shown). However, this discrepancy reflects the
importance of working in the context of the whole virus,
where different long-range interactions and secondary
and tertiary structures than those observed in vitro
[10,12,27] might influence the ability of the genome to
form a dimer. Furthermore, a number of factors such as
the Gag and nucleocapsid (NC) proteins, which have
been shown to promote dimerisation [10,27-30], are only
present in the context of the virus.
Encapsidation efficiencies of the HIV-2 mutants
Deletion of the DM sequence (Fig. 1A) was previously
reported to cause a severe packaging defect in HIV-2 [8].
Northern blot analysis of the SM2 mutant revealed a pos-
sible defect in encapsidation (Fig. 2A), even though only
four bases of the Psi region are substituted in this mutant.
To investigate this further, we assessed the level of HIV-2
genomic RNA in the cytoplasm of transfected cells and
pelleted virions using RNase Protection Assay (RPA, Fig.
3). Wild type and mutant genomic RNAs were detected by
probing with KS2ΨKE (Fig. 3B) and the size of the pro-
tected fragments are shown in figure 3A. A specific ribo-
probe (KS2ΨEP) was used to measure plasmid DNA
contamination (Fig. 3B). Finally, equal loading of cyto-
plasmic RNA was confirmed by probing for GAPDH
mRNA (Fig. 3B). Packaging efficiencies, taken as the ratio
of virion to cytoplasmic RNA of a mutant relative to the
wild type, are reported in figure 3C. As observed in figure
2A, the SM2 mutant displayed some reduction in packag-
ing (approx. 40% on average). Although this figure is
lower than for the DM deletion mutant, which showed a
70% decrease in RNA encapsidation, statistical analysis
revealed that the difference in the packaging efficiencies of
these two mutants was not significant. By contrast, the
SM1 mutation of the DIS did not affect HIV-2 RNA encap-
sidation (Fig. 3C).
Mutations in HIV-2 packaging signal, but not in the DIS, render the RNA monomeric in vivo Figure 2
Mutations in HIV-2 packaging signal, but not in the DIS, render the RNA monomeric in vivo. (A) Native northern 
blot analysis of HIV-2 genomic RNA extracted from pelleted virions 48 h after COS-1 cell transfection. RNA inputs were nor-
malised on RT activity and an equivalent to 2.5 × 106 cpm was used. WT, wild type; DM, Psi deletion mutant; SM1, DIS mutant; 
SM2, Psi pal mutant; mock, mock transfection; MM, Millennium RNA Markers (Ambion); M, monomer; D, dimer. (B) Bar chart 
representing the percentage of dimer present in each virion RNA sample. Data from at least three independent experiments 
are shown, error bars correspond to the SD. *, Student t test p value < 0.05.Retrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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Viruses with mutations in the packaging signal and 
impaired dimerisation fail to replicate in T cells
Since the SM2 mutant exhibited a comparable reduction
in the level of dimer as the DM mutant, but retained a
greater portion of the HIV-2 packaging determinant and
possibly encapsidated its genome more efficiently than
the DM mutant, it was of interest to compare the replica-
tion kinetics of these two mutants (Fig. 4). Despite having
no defect in RNA encapsidation or dimerisation, the SM1
mutant was included to verify that mutation of the DIS
does not impair viral replication over a longer period of
time. As shown on figure 4, viral spread in the DM and
SM2 mutants was markedly reduced and the mutant
viruses were not able to revert to a replication competent
phenotype despite prolonged culture. The similar behav-
iour of the DM and the SM2 mutants suggest that a failure
to encapsidate a dimeric genome rather than just a reduc-
tion in encapsidation might be responsible for the replica-
tion defect observed. Indeed, viral RNA dimerisation has
been associated with viral infectivity in other retroviruses
[16,19,31,32]. The SM1 mutant virus replicated as effi-
ciently as wild type virus, confirming that an intact DIS
palindrome is dispensable for the establishment of a pro-
ductive infection.
Encapsidation efficiency of the Psi and DIS HIV-2 mutants Figure 3
Encapsidation efficiency of the Psi and DIS HIV-2 mutants. (A) Size of the protected fragment corresponding to the 
viral genomic RNA when using the KS2ΨKE riboprobe in an RNAse protection assay (RPA). Protected mutant genomic RNAs 
vary in size between 329 and 355 nt due to the position of the mutations. (B) Representative RPA where 2 µg of cytoplasmic 
RNA and an equivalent of 2.5 × 106 cpm of virion RNA was probed with 1 × 105 cpm of KS2ΨKE riboprobe. Samples were also 
probed with 1 × 105 cpm of KS2ΨEP and GAPDH riboprobes to detect plasmid DNA contamination and control for the load-
ing, respectively. WT, wild type; DM, Psi deletion mutant; SM1, DIS mutant; SM2, pal mutant; mock, mock transfection; Y, yeast 
RNA + RNase; I, yeast RNA – RNAse (diluted 1:10); M, Century Plus RNA Markers (Ambion). (C) Packaging efficiencies of 
mutant HIV-2 relative to WT virus. Data from 3 independent experiments are shown, error bars correspond to the SD. *, Stu-
dent t test p value < 0.005.Retrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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Dimerisation deficient viruses display a reduced infectivity 
disproportionate to the packaging defect
Although we now had evidence that mutation of the DM
region, including pal, altered both genomic RNA encapsi-
dation and dimerisation, it was important to know
whether this alone was responsible for the very poor rep-
lication of the DM and SM2 viruses in T cells. Hence, we
examined whether the mutant viruses were impaired in
infectivity using the Ghost CCR5/CXCR4 reporter cell line
which contains a stably transfected reporter cassette, con-
sisting of an HIV-2 LTR driving expression of a green fluo-
rescent protein (gfp) gene. Successful infection of these
cells by HIV-2 leads to activation of the cassette by the
newly synthesised Tat protein and can be detected by
measuring GFP production in the infected cells. We com-
pared the infectivity of VSV-G pseudotyped wild type and
mutant virions. Both the DM and the SM2 mutants
showed a strikingly lower level of infectivity when equiv-
alent amounts of virus, as measured by RT activity, were
used to infect the Ghost cells (Fig. 5A). As observed in T
cells, the SM1 mutation had no effect on the ability of the
virus to infect permissive target cells. The envelope-
deleted viruses or VSV-G envelope had no effect on GFP
expression when the corresponding plasmids were trans-
fected individually into COS-1 cells (data not shown).
The VSV-G envelope was used to pseudotype envelope-
deleted HIV-2. This may influence the ability of the virus
to enter and hence infect the target cells because of the
postulated difference in entry mechanism using this enve-
lope. However, a preliminary experiment was carried out
using full-length wild type and DM mutant HIV-2. Hela
cells stably transfected with a reporter cassette, consisting
of an HIV-1 LTR driving expression of a beta-galactosidase
gene, were used. Similar results as those observed in the
Ghost CCR5/CXCR4 cells were obtained (data not
shown), even though the high level of background stain-
ing rendered the determination of an exact infectious titre
difficult.
The reduced infectivity observed could be due to the
defective packaging of the DM and SM2 viruses and thus
the delivery of fewer genomes to the Ghost cells. There-
fore, we were concerned to ensure that the absolute quan-
tity of genomic RNA delivered to the Ghost cells was
similar for wild type and mutant viruses. Since we have
shown that the DM deletion virus displayed a three fold
reduction in RNA encapsidation (Fig. 3C), we augmented
the DM virus input by three fold so that a comparable
number of genomes would be delivered to the Ghost cells
(Fig. 5B). We verified the level of HIV-2 genomic RNA in
two viral inputs by semi-quantitative RT-PCR performed
on serial dilutions of the virus inoculum (Fig. 5B, top
panel). To ensure that the RNA extraction process did not
result in a loss of RNA, leading to differences in genomic
RNA levels, a GAPDH carrier RNA was added prior to the
extraction and analysed in parallel by RT-PCR as an inter-
nal control (data not shown). Interestingly, targeting
equivalent numbers of HIV-2 genomes to the Ghost cells
did not lead to equivalent infectivity (Fig. 5B). With both
inputs tested, infectivity of the DM virus was three to five
Mutations in the HIV-2 packaging signal affect replication of HIV-2 in T-cells Figure 4
Mutations in the HIV-2 packaging signal affect replication of HIV-2 in T-cells. 1 × 106 Jurkat T-cells were infected 
with an amount of virus equivalent to 1 × 107 cpm as measured by RT activity assay. Replication was assessed by measure of 
the RT activity every 4 days. Cells were passaged 1/2 every 8 days but no new cells or viruses were added at any point during 
the course of the infection. Data from two independent experiments are shown. Error bars represent the SD.Retrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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Virus infectivity is decreased by mutations in the Psi region Figure 5
Virus infectivity is decreased by mutations in the Psi region. (A) Viral infectivity was determined using a reporter cell 
line expressing the gfp gene under the control of the HIV-2 LTR (Ghost CCR5/CXCR4). Equivalent amounts of VSV-G pseu-
dotyped wild type (WT) and mutant HIV-2, normalised on RT activity, were used to infect 5 × 103 Ghost CCR5/CXCR4 cells 
and expression of GFP was measured at 72 h post-infection by FACS. Data from at least three independent experiments are 
plotted. Error bars represent the SD. (B) Virus inputs were adjusted according to the DM virus packaging defect as to infect 
the Ghost cells with an equivalent level of genomic RNA for WT and DM virus. Top panel: HIV-2 genomic RNA was extracted 
from two set amounts of virions used to infect the Ghost cells and viral RNA levels were assessed by semi-quantitative RT-
PCR using neat, 1:10 and 1:100 dilution of the RNA sample. A GAPDH carrier RNA was added during the extraction and 
amplified in parallel by RT-PCR to control for RNA loss during the RNA extraction (not shown). A control without RT was 
performed on 10 µl of neat RNA (-). Bottom panel: The percentage of GFP positive cells was measured by FACS at 72 h post-
infection. Arbitrary levels of RNA of 1 and 4 are equivalent to 62.5 cpm and 250 cpm of WT virus, respectively, as measured 
by RT activity assay. Data from four independent experiments are shown on the chart. Error bars represent the SD. *, Student 
t test p value < 0.05; **, p value < 0.01.Retrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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fold lower than that of the wild type virus. These results
show that the infectivity defect seen in figure 5A was not
simply a consequence of reduced numbers of virus
genomes entering the Ghost cells.
Encapsidation of a dimeric genome is important for HIV-2 
particle maturation
To investigate whether there was any contribution of RNA
encapsidation and genome dimerisation to viral assembly
in HIV-2, we purified virions produced by cells transfected
with either wild type or DM deletion provirus, both enve-
lope-deleted, and analysed them using electron micros-
copy and negative staining. Electron micrographs were
examined by two independent observers and approxi-
mately two hundred particles were identified for each
virus. Representative particles containing immature,
mature and multiple cores are shown in figure 6A (i), (ii)
and (iii), respectively. We observed that cells transfected
with the DM proviral DNA produced significantly fewer
mature particles as compared to those transfected with
wild type provirus (Fig. 6B). Surprisingly, the loss of
mature particles for the DM virus was not accompanied by
an increase in the proportion of immature virions (Fig.
6B). However, there was a larger number of duplex cores
in the DM deletion virions, although this difference does
not appear to be statistically significant (Fig. 6B). Further-
more, the existence of multiple cores in mature virions has
been documented previously for the related virus HIV-1
[33]. These results show that a mutation in the HIV-2
packaging signal that also affects genome dimerisation
leads to a reduction in the number of mature particles and
an abnormal proportion of particles containing more
than one core, possibly explaining the loss of infectivity
associated with this mutation. Finally, it was also notable
that the average diameter of the mutant virions was larger
than that of the wild type virions (Fig. 6C). This did not
appear to solely result from an increased number of parti-
cles containing multiple cores, unlike in HIV-1, where
particles containing two cores were significantly larger
than those containing a single core [33]. Taken together,
these results suggest that genomic RNA encapsidation,
genome dimerisation and virion particle morphology are
extremely closely linked in HIV-2.
Discussion
We have explored the SL-1 region of the HIV-2 5' leader
and shown that a signal essential for in vivo dimerisation
in the viral particle is disrupted when the packaging signal
is mutated. Substitution of four nucleotides in the Psi pal-
indrome is sufficient to partially impair dimerisation and
encapsidation of the virus, suggesting that the two proc-
esses may be linked. This result confirms a previous report
showing that the Psi palindrome is involved in RNA dim-
erisation in HIV-2 [11,20].
Deletion of the whole Psi region significantly reduces the
level of dimeric genome in the virions, in addition to
causing a strong encapsidation defect.
While both Psi mutants exhibited a similar decrease in the
percentage of dimer present (30% and 35% for DM and
SM2, respectively), a large variation was observed. This
reflects the difficulty of quantifying the dimeric RNA
bands using densitometry. Indeed, the RNA dimer does
not migrate as a distinctive neat band but rather as a vari-
ably spread band. In addition, it is not always possible to
clearly distinguish the end of the dimer band from the
beginning of the monomer band and the background in
between. This is not a problem when analysing a virus
that dimerises well, as the very strong intensity of the
dimer band renders it easier to delimit and quantify (e.g.
WT and SM1, Fig. 2A). Hence, even though the variation
may appear quite large for the DM and the SM2 mutants,
both viruses exhibited a significant reduction in the level
of dimeric RNA packaged.
Similarly, although the defect in genomic RNA encapsida-
tion observed for the DM mutant appears more pro-
nounced than that observed for the SM2 mutant, both
mutants encapsidated significantly less RNA than the wild
type virus. Since only four bases were mutated in the SM2
virus as compared to a deletion of 28 nt in the DM virus,
it might explain the difference in the packaging efficien-
cies of DM and SM2. Furthermore, the stability of the
genomic RNA dimer of the DM and SM2 mutant may not
be the same and could influence the ability of these
viruses to encapsidate their genomes. Further work in our
laboratory will aim to determine if the different mutations
introduced in the 5' UTR of HIV-2 affect the stability of the
RNA dimer. This will help establish whether the same
mechanism is involved in the reduction of viral infectivity
observed with the DM and SM2 mutants.
The RNA dimer was shown to undergo protease-depend-
ent maturation in Murine leukaemia virus (MuLV) and
HIV-1 [30,34], although it was later demonstrated that
Gag cleavage alone was not sufficient to promote dimer
maturation [35]. The proteolytic processing of the p2/CA
cleavage site and the spacer peptide p1 have both been
implicated in the stability and maturation of the HIV-1
RNA dimer [36,37]. To date, it remains unclear as to
whether the reduction in the level of dimer detected in the
DM and SM2 mutant virions results from a defect in the
dimer formation or a decrease of the dimer stability.
A recent study of HIV-1 dimerisation proposed that
genomic RNA is packaged as a monomer and that dimer-
isation subsequently occurs at the DIS in a three-step pro-
tease-dependent mechanism [38], although several other
studies in HIV-1 and MuLV suggested that dimerisationRetrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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Efficient dimerisation and encapsidation are associated with correct assembly and particle maturation in HIV-2 Figure 6
Efficient dimerisation and encapsidation are associated with correct assembly and particle maturation in HIV-
2. COS-1 cells were transfected with envelope-deleted provirus and virions were harvested 48 h later. Purified HIV-2 particles 
were analysed by negative staining and electron microscopy. (A) Five examples of what were assessed as immature particles (i), 
mature particles (ii) and particles containing multiple cores (iii) are shown. Scale bar: 100 nm. (B) The proportion of mature, 
immature and multiple core particles was calculated for wild type (WT) and DM mutant HIV-2 after examination of 193 WT 
and 199 DM particles by two individuals independently. Error bars correspond to the SD. *, Student t test p value < 0.05. (C) 
The particles were measured and the average sizes of WT and DM particles were reported on the graph. Error bars corre-
spond to the SD; n=215 for WT and 189 for DM; *, Student t test p value < 0.05.Retrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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might have already occurred within the infected cell
[15,17,39,40]. Therefore, it would of interest to analyse
whether the formation of dimeric HIV-2 genomic RNA
occurs prior to encapsidation or involves a protease-
dependent step.
The DM mutant shows a defect in infectivity that is inde-
pendent of the reduction in encapsidation, as targeting a
similar amount of genome to the target cells does not
restore infectivity. Furthermore, both viruses mutated in
the Psi region were unable to establish a productive infec-
tion in T cells, suggesting that encapsidation of a dimeric
genome might be required for viral infectivity in HIV-2.
This involvement of SL-1 in RNA encapsidation and dim-
erisation has been reported for simian immunodeficiency
virus macaque (SIVmac), where mutations in this region
also resulted in a reduction in viral infectivity [19].
Interestingly, introduction of a mutation in the DIS palin-
drome so that it was no longer self-complementary did
not yield any decrease in the level of dimeric genome in
vivo. This result contradicts previous in vitro studies where
an SL-1-mediated dimerisation [21,22] was proposed to
be regulated by several long-range interactions [10,11,27].
However, in the context of the virus, different interactions
and conformational changes might occur and trans-acting
factors such as the Gag protein have been shown to pro-
mote dimerisation in HIV-1 and MuLV [28,29]. Further-
more, in HIV-1, the DIS palindrome was also reported to
be dispensable for dimerisation in vivo [25] and replica-
tion in primary cells [26]. However, an intact HIV-1 DIS
was required for efficient RNA packaging and viral replica-
tion in T cells [16,25,32], which we did not observe in
HIV-2. This suggests that the palindrome termed the DIS
in HIV-2 is not an important Dimer Initiation Site in vivo,
even though it might be involved at some stage of the
dimer formation.
In the mutants of the Psi region studied here, there was a
correlation between an encapsidation and a dimerisation
defect, indicating that the two processes may be closely
linked, as previously proposed for HIV-1, HIV-2 and
MuLV [11,16,25,32,40]. This suggests either that one is
dependent on the other or that the same or closely adja-
cent sequences are responsible for both processes.
The dimeric RNA genome has been shown to have a
number of different roles in several stages of the retroviral
life cycle, such as recombination during reverse transcrip-
tion [39,41] and proviral DNA synthesis [16,42,43]. In
addition, RNA was proposed to have a structural role in
MuLV [44]. We have now shown that, in HIV-2, the
absence of a dimeric genome is associated with a severe
replication defect which is disproportionately large com-
pared to the diminution in RNA encapsidation. Packaging
of monomeric genomes occurs but is less efficient than
that of dimeric ones. However, delivery of viruses contain-
ing monomeric genomes to target cells is characterised by
a reduction in infectivity which cannot be restored simply
by increasing the number of genomes delivered. Thus, it
seems that a monomeric genome impairs virus viability.
Previous studies have shown that RNA capture influences
viral assembly by both affecting the efficiency and con-
tributing to normal capsid morphology [1,19,44,45]. In
SIV, mutations in the SL-1 region that resulted in a reduc-
tion of encapsidation and dimerisation also led to aber-
rant particle morphology [19]. EM of our viruses
containing monomeric genomes shows that there is a sig-
nificant reduction in particle maturation compared to
when the dimeric genome is present and that larger cores
can be detected. However, the proportion of immature
particles in the mutant virus sample is similar to that of
the wild type virus preparation, indicating that the mutant
viruses undergo at least some degree of maturation. Fur-
thermore, protein processing of the DM mutant appeared
normal when analysed at the same time point of 48 hrs
post-transfection that we used in this study [8]. Nonethe-
less, a delay in protein processing cannot be excluded as
the analysis was only performed at a single time point. In
HIV-1, mutations of the DIS were reported to cause a
delay in the processing of the p2 peptide [46], which has
been demonstrated to be involved in the sequential prote-
olytic processing of the Gag protein [47]. In addition,
RNA was proposed to be required for the cleavage of the
HIV-1 NCp15 precursor [48], suggesting that binding of
the nucleocapsid protein to the RNA might play a role in
virion maturation. With this in mind, it would be interest-
ing to analyse the protein processing of the mutant virus
at several time points and determine whether the process-
ing of the Gag and Gag-Pol polyproteins is affected.
Intriguingly, there is an increased number of particles con-
taining duplex cores in the DM deletion virions. This phe-
nomenon has previously been observed in HIV-1, where
approximately 30% of the particles contained two cores
[33]. Since we have shown here that the DM virions con-
tain predominantly monomeric RNA, it is tempting to
speculate that these cores each contain a single mono-
meric genome, although proving this rigorously will be
challenging.
Our work is consistent with dimeric RNA being involved
in efficient packaging in HIV-2. In MuLV, recent structural
studies have implied that dimerisation of the genomic
RNA leads to exposure of a high affinity Gag binding site
in vitro [15], suggesting that dimeric RNA is important for
the Gag:RNA interaction. Therefore, it would be of great
interest to analyse whether our mutations in the SL-1/PsiRetrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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region affect the binding affinity of the Gag protein to the
RNA.
It remains to be seen whether the encapsidation process in
other Lentiviruses, and particularly HIV-1, is also depend-
ent on formation of an RNA dimer prior to Gag capture.
Molecules which interfere with this process might be
exploited as antiviral agents and would be expected to
have a high degree of selectivity for the virus, since RNA
export is virus specific in animal cells and export of a
dimeric species is, as far as we know, unique to retrovi-
ruses. Indeed, there is recent evidence that oligonucle-
otides targeting the dimer linkage of HIV-1 are effective
antiviral agents in vitro [49].
Conclusion
In this study, we have shown that in HIV-2, the cis-acting
packaging and dimerisation elements are closely linked
and may be part of the same structural region of the 5'
UTR. Surprisingly, the DIS does not mediate HIV-2
genomic RNA dimerisation in vivo and does not seem to
play a significant role in viral replication or infectivity.
Packaging a monomeric genome appears to adversely
affect the production of infectious viral particles and the
virions that are produced have an abnormal morphology.
It therefore seems likely that the dimeric genome plays an
important role in the virion, both from its coding poten-




pSVR is an infectious proviral clone of HIV-2 ROD con-
taining a simian virus 40 origin of replication [7]. Restric-
tion sites and nucleotide numbering, where given, are
relative to the first nucleotide of the viral RNA. Proviral
construct pSVRDM containing a 28 nt deletion in the 5'
leader has been previously described [8]. Mutations in the
5' leader were introduced by site-directed mutagenesis
[50] into a subclone of HIV-2, pGRAXS [8], using primers
5' GGCGCGGGCCGACCAACCAAAGGCAGCGTGTGG 3'
and its complement and 5' GGAACAAACCACGAC-
CCTCTGCTCCTAGAAAGGCG 3' and its complement for
SM1 and SM2, respectively. Sequences from the resulting
subclones were introduced into the provirus by exchang-
ing an AatII-XhoI fragment, generating proviral constructs
pSVRSM1 and pSVRSM2. Proviral constructs pSVR∆NB
and pSVR∆NBDM which contain a 550 nt deletion in the
env gene (positions 6369 to 6927) have been previously
described [8]. pSVR∆NBSM1 and pSVR∆NBSM2 were
generated by replacing the AatII-XhoI region of pSVR∆NB
with the same region of pSVRSM1 and pSVRSM2 respec-
tively. pCMV-VSVG contains the vesicular stomatitis virus
(VSV) G glycoprotein gene in the context of pCDNA3
(Invitrogen). All plasmids based on HIV-2 proviral
sequences were grown in TOPF'10 (Invitrogen) Escherichia
coli at 30°C to avoid recombination. All other plasmids
were grown in DH5α E. coli under standard conditions.
Plasmids used as template for production of riboprobes
were constructed as follows. Plasmids KS2ΨKE and
KS2ΨEP have been previously described [8,51]. They con-
tain HIV-2 sequences from positions 306 to 751 and (-
107) to 306 of pSVR, respectively, cloned into the
polylinker of the pBluescript KSII(+) transcription vector
(Stratagene). A glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) riboprobe template was created by reverse
transcriptase (RT)-PCR amplification of the sequence
from position 61 to 346 of human GAPDH using 5' GGT-
GAAGGTCGGAGTCAACG 3' and 5' AATTAACCCT-
CACTAAAGGACTCCACGACGTACTC 3' primers. Total
cytoplasmic RNA extracted from Jurkat T cells served as
template for the reaction. In vitro transcription of the line-
arised plasmids and PCR fragment using T3 RNA
polymerase yielded antisense riboprobes for use in the
northern blot and RNase protection assay (RPA).
Cell culturing and transfection
COS-1 simian epithelioid cells, obtained from the Euro-
pean Collection of cell culture (ECACC), were maintained
in Dulbecco's modified Eagle's medium (DMEM, Gibco
BRL) supplemented with 10% fetal calf serum and 1×
penicillin/streptomycin (Invitrogen). Cells were trans-
fected in 10 cm-diameter dishes by the DEAE-dextran
method [52] with a total of 5 µg of DNA. Cells and super-
natants were harvested 48 h later, and virus production
was assessed with a RT assay [53]. CD4+ human osteosar-
coma (HOS) cells stably transfected with CCR5, CXCR4
and the green fluorescent protein (gfp) reporter gene
under the control of HIV-2 LTR (designated Ghost CCR5/
CXCR4), provided by the Centralised Facility for AIDS
Reagents, NIBSC, UK, were maintained in DMEM supple-
mented with 10% fetal calf serum, 1× penicillin/strepto-
mycin (Invitrogen), 100 µg/ml hygromycin (Invitrogen),
500 µg/ml geneticin (Gibco BRL) and 1 µg/ml puromycin
(Sigma) as previously described [54]. Jurkat T cells, pro-
vided by the Centralised Facility for AIDS Reagents,
NIBSC, UK, were maintained in RPMI 1640 medium
(Roswell Park Memorial Institute, Gibco BRL) supple-
mented with 10% fetal calf serum and 1× penicillin/strep-
tomycin (Invitrogen).
T-cell replication assay
Replication assays were performed as described previously
[8] with the following modifications. Pelleted virus from
two individual transfections were resuspended in 500 µl
RPMI 1640 each and pooled. Subsequently, an amount of
virus equivalent to 1 × 107 cpm of RT activity was added
to 1 × 106 Jurkat cells in the presence of 10 µg/ml DEAE-
dextran in one well of a 6-well culture plate. After 24 h atRetrovirology 2007, 4:90 http://www.retrovirology.com/content/4/1/90
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37°C, cells were transferred into a 25 cm2 flask containing
10 ml of media and virus replication was followed by
measuring RT activity every 4 days. Cells were split 1/2
every 8 days.
Transduction of HOS-CD4+ LTR-GFP cells
Supernatants of COS-1 cells transfected with 5 µg enve-
lope-deleted provirus and 5 µg VSV-G expressor plasmid,
10 µg envelope-deleted provirus alone or 10 µg VSV-G
expressor alone as well as mock transfected cells were har-
vested as previously described [8] except that pelleted
virus from two individual transfections were resuspended
in 500 µl DMEM each and pooled. The RT activity of the
resulting virus preparation was determined as described
above and the amount of virus added to a 6-well plate of
cells was normalised this way. Ghost CCR5/CXCR4 cells
were seeded at 2 × 105 cells per well in selection medium
24 h prior to infection. Cells were exposed to increasing
amount of WT and mutant viruses in the presence of 8 µg/
ml polybrene (Sigma) for 16 h, after which the virus-con-
taining medium was replaced by fresh selection medium.
At 72 h post-infection, cells were washed twice with cold
PBS, trypsinised and fixed in 2% paraformaldehyde. GFP
expression was measured by FACS analysis.
RT-PCR
Viral RNA from normalised amounts of virions was iso-
lated using the QiAamp viral RNA kit (Qiagen). 1 µg of in
vitro synthesised GAPDH RNA (pos. 61 to 346) was added
to each sample prior to extraction. The extracted RNA was
treated with 5 U TURBO DNase (Ambion) for 1 h at 37°C,
followed by heat inactivation for 10 min at 65°C. 10 µl of
neat RNA, 1:10 or 1:100 dilution were used for RT-PCR
using One step RT-PCR kit (Abgene) with HIV-2 Psi F 5'
TAATACGACTCACTATAGGCTGAGTGAAGGC 3' and Psi
R 5' AGGTACTTACCTTCACCC 3'. A control without RT
was performed with 10 µl of neat RNA. Samples were vis-
ualised on a 2% agarose gel.
RNA isolation
Cytoplasmic and virion RNAs were harvested with the
RNAeasy mini kit (Qiagen) and the QIAamp viral RNA kit
(Qiagen), respectively. The isolated RNA was treated with
5 U of TURBO DNase (Ambion) for 30 min at 37°C and
extracted once with acid-buffered phenol-chloroform and
once with chloroform. RNA was precipitated with ammo-
nium acetate and ethanol and stored at -80°C.
Northern blot analysis
KS2ΨKE biotinylated riboprobe was synthesised by in
vitro  transcription of linearised plasmid using T3 RNA
polymerase (Promega), and purified with a G-50 column
(Roche) prior to use in northern blot assays. Reagents for
the northern blots were obtained from a commercially
available kit (Ambion). Virion RNA input was normalised
on RT activity, with an equivalent of 2.5 × 106 cpm being
the standard amount used per reaction. RNAs were sub-
jected to non-denaturing electrophoresis on 0.8% LE-aga-
rose (Ambion) gel. For size determination, biotinylated
RNA Millennium markers (Ambion) were run in parallel.
RNAs were transferred onto positively charged nylon
membranes (Ambion) prior to incubation with 0.4 nM
riboprobe for 16 h at 68°C. Detection was performed
using the BrightStar Biodetect kit (Ambion). RNA was
quantified by densitometry using the ImageJ software.
RNase protection assays
[α-32P]-labelled KS2ΨKE riboprobe was synthesized by in
vitro  transcription of linearised plasmid using T3 RNA
polymerase (Promega) and gel purified prior to use in
RPA, as described previously [8]. RNA inputs were nor-
malised on concentration, for cytoplasmic RNA, and RT
activity, for virion RNA. Typically, 2 µg of cytoplasmic
RNA and an equivalent of 2.5 × 106 cpm of viral RNA were
used. For each experiment, a separate RPA was performed
using the same RNA inputs but probing for viral plasmid
DNA using a probe generated from plasmid KS2ΨEP. In
addition, a probe for human GAPDH RNA was included
in the reaction to control for variations in cytoplasmic
RNA input. Any DNA contamination or variations in the
GAPDH signal were accounted for when calculating
encapsidation efficiencies, taken as the ratio of virion to
cytoplasmic RNA of a mutant relative to the wild type.
Electron microscopy
Supernatants of COS-1 cells transfected with envelope-
deleted WT and DM deletion mutant proviruses were har-
vested as previously described [8]. Pelleted virions were
resuspended in 10 µl of 100 mM NaCl, 50 mM MOPS
buffer at 4°C for 24 h prior to negative staining. 0.8 µl of
virion preparation was applied to a carbon coated grid
and stained with a few drops of 1% uranyl acetate. Micro-
graphs were recorded on a Philips EM208S at a nominal
magnification of × 20,000.
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